US EditionBerger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
- Berger Montague PC is investigating Rocket Pharmaceuticals, Inc. over a newly filed securities class action lawsuit.
- The lawsuit claims Rocket Pharmaceuticals misled investors about important safety disclosures related to its RP-A501 gene therapy program.
- Following news of a patient death, Rocket Pharmaceuticals' stock dropped nearly 37%, from $6.27 to $2.33.
- Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may seek recovery, with a lead plaintiff deadline of August 11, 2025.
52 Articles
52 Articles
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
PHILADELPHIA, July 9, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company").…
#A Balancing Act Rocket Pharmaceuticals Legal Hurdles and Financial Resilience,
'Rocket Pharmaceuticals Faces Class Action Lawsuit amidst Improved Financial Metrics' Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a prominent player in the biopharmaceutical industry, is currently navigating through a challenging legal landscape. The Pomerantz Law Firm recently announced a class action lawsuit filed against Rocket Pharmaceuticals. This development comes as a significant point of interest for investors and industry analysts, lau…
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
